J Korean Med Assoc.  2008 Feb;51(2):168-175. 10.5124/jkma.2008.51.2.168.

Extensively Drug Resistant-Tuberculosis, XDR-TB

• Park JS

• KMID: 2185734
• DOI: http://doi.org/10.5124/jkma.2008.51.2.168

Abstract

Multidrug-resistant tuberculosis(MDR-TB), resistant to at least the two main TB drugsisoniazid and rifampicin, has been a threat to TB control because the treatment requires more toxic drugs and longer period with poor treatment outcomes. Recently, more serious concerns have been raised about extensively drug resistant-tuberculosis (XDR-TB), which shows resistance to fluoroquinolones and aminoglycosides in addition to isoniazid and rifampicin. XDR-TB is a serious global health threat because the cure is very difficult as few sensitive anti-TB drugs remain. XDR-TB develops when first-and second-line anti-TB drugs are misused during the course of treatment, most commonly due to poor compliance of the patients to the treatment regimen. People with XDR-TB can pass the XDR-TB bacteria to other people. Thus, every effort should be made to prevent the development of XDR-TB by establishing an effective TB control program maximizing patient adherence to prescribed anti-TB regimen and minimizing contact of XDR-TB patients with other people to prevent the spread of XDR-TB.

Keyword

Tuberculosis; Multidrug-resistant; Extensively drug-resistant

MeSH Terms

Aminoglycosides
Bacteria
Compliance
Extensively Drug-Resistant Tuberculosis
Fluoroquinolones
Humans
Isoniazid
Patient Compliance
Rifampin
Tuberculosis
Aminoglycosides
Fluoroquinolones
Isoniazid
Rifampin

Reference

1. Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest. 2006. 130:261–262.

2. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR. 2006. 55:1176.

3. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007. 45:1409–1414.

4. Helen SC, Stobdan K, Sholpan A, Vinciane S, Zinaida NT, Sabine RG, Hamraev AK, Yared K, Clair M. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan Uzbekistan: Treatment complexity and XDR-TB among treatment failure. PLos One. 2007. 2:e1126.

5. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR. 2007. 56:250–253.

6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR. 2006. 55:301–305.

7. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Frienland G. Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006. 368:1575–1580.

8. Singh S, Sankar MM, Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS. 2007. 21:2345–2347.

9. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug resistant tuberculosis. Clin Infect Dis. 2007. 45:1290–1295.

10. Lee JY, Choi HJ, Lee HY, Joung EY, Huh JW, Oh YM, Lee SD, Kim DS, Kim WD, Shim TS. Recovery rate and characteristics of nontuberculous mycobacterial isolates in a university hospital in Korea. Tuber Respir Dis. 2005. 58:385–391.

11. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Javashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007. 51:576–582.

12. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Cehmother. 2005. 56:180–185.

13. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003. 47:1824–1831.

14. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med. 2001. 162:1055–1058.

15. Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet. 2006. 367:945–947.

16. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglilon M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther. 2007. 5:857–871.

17. Kim HJ. Current situation of tuberculosis and its control in Korea. J Korean Med Assoc. 2006. 49:762–772.